FDA inspection
GlaxoSmithKline dba Human Genome Sciences Inc: FDA inspection ending Dec 11, 2023
FDA inspection 1226290 · Voluntary Action Indicated (VAI) · Rockville, MD
Key facts
| Inspection ID | 1226290 |
|---|---|
| Firm | GlaxoSmithKline dba Human Genome Sciences Inc |
| FEI number | 3003782237 |
| Address | 9910 Belward Campus Dr |
| City | Rockville |
| State | MD |
| ZIP | 20850-3957 |
| Fiscal year | 2024 |
| Inspection end date | Dec 11, 2023 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | New Drug Evaluation |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data